CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Glembatumumab Vedotin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02363283
NCT02363283Phase 2Completed
CompareCT.gov

A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma

National Cancer Institute (NCI)·interventional·Posted Feb 16, 2015·Updated Aug 21, 2020

In Brief

A Phase 2 clinical trial evaluating Glembatumumab Vedotin, Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Uveal Melanoma and Stage IV Uveal Melanoma AJCC v7. Completed, enrolled 37 participants across 25 sites.

Detailed Summary

This phase II trial studies how well glembatumumab vedotin works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the body (metastatic) or has returned at or near the same place after a period of time during which the cancer could not be detected (locally recurrent). Glembatumumab vedotin may shrink the tumor by binding to tumor cells and delivering tumor-killing substances to them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 16, 2015
Enrollment StartSep 16, 2015
Primary CompletionJul 2, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.4 years ago

Interventions

Glembatumumab Vedotindrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies

Pharmacological Studyother

Correlative studies